WHEREAS Defendant Annora Pharma Private Limited ("Annora") filed Abbreviated New Drug Application No. 214831 ("ANDA No. 214831") seeking approval from the U.S. Food and Drug Administration ("FDA") to engage in the commercial manufacture, use, and sale of 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg brivaracetam tablets ("Annora's ANDA Product") prior to the expiration of U.S. Patent No. 6,911,461 (the "'461 Patent"); WHEREAS Defendants Apotex Inc. and Apotex Corp. (collectively, "Apotex") filed Abbreviated New Drug Application No. 214875 ("ANDA No. 214875") seeking approval from the FDA to engage in the com1nercial manufacture, use, and sale of 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg brivaracetam tablets ("Apotex 's ANDA Product") prior to the expiration of the '461 Patent; WHEREAS Defendants MSN Laboratories Private Limited and MSN Pharmaceuticals Inc. (collectively, "MSN") filed Abbreviated New Drug Application Nos. 214921 ("ANDA No. 214921"), 214922 ("ANDA No. 214922"), and 214924 ("ANDA No. 214924") seeking approval from the FDA to engage in the commercial manufacture, use, and sale of 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg brivaracetam tablets, 10 mg/ml oral solution, and 50 mg/ml intravenous solution ("MSN's ANDA Products") prior to the expiration of the '461 Patent; WHEREAS the Court held a four-day bench trial on November 14-18, 2022. WHEREAS on August 16, 2023, the Court issued its Opinion (D.I. 246) and Order (D.I. 247) finding that Claim 5 of the '461 Patent is infringed and not invalid; WHEREAS before trial, U.S. Patent No. 6,784,197 and U.S. Patent No. 8,492,416 expired (collectively the "Expired Patents"); IT IS HEREBY ORDERED AND ADJUDGED, for the reasons set forth in the August 16, 2023 Opinion, that: Judgment is entered in of Plaintiff and against MSN on Plaintiffs- claim that MSN's filings of ANDA 214921. 214922, and 214924 infringed Claim 5 ofthe '461 Patent and that the commercial manufacture, use, sale Or for sale in the United States, or importation into the United States, ofMSN's ANDA Products would infringe Claim 5 of the '461 Patent. 2. Judgment is entered in Of plaintiffs and against MSN on MSN's counterclaims for invalidity or unenforceability and non-infringement Claim 5 of the '461 Patent 3. Pursuant to 35 US.C. § the effective date of any final approval of MSN's ANDA Products shall be a date that is not earlier than the date of expiration of the '461 Patent and any additional periods Of exclusivity to which Plaintiffs have or may become entitled.4. Pursuant to 35 U.S.C. § 271(e)(4)(B), Annora and each of its officers, agents, servants, employees, successors, and attorneys, and all persons and entities acting in concert or participation with them, are enjoined , until the expiration of the '461 Patent from commercially manufacturing, using, selling or offering for sale in the United States, or importing into the United States, Annora's ANDA Products. 5. Plaintiffs' claims for infringement and Annora's counterclaims for invalidity and non-infringement of the Expired Patents are dismissed as moot.